


Please type a plus-sign, (+) inside this box → ☐

PTO/SB/17 (12/97)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FEE TRANSMITTAL

Note: Effective November 10, 1998.
Fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$920.00)

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:
Deposit Account Number: 05-0840
Deposit Account Name: Eli Lilly and Company

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. CLAIMS

Total Claims	Extr a	Fee from below	Fee Paid
<input type="checkbox"/> -20**	<input type="checkbox"/>	18	
<input type="checkbox"/> Independent Claims	<input type="checkbox"/>	84	
<input type="checkbox"/> Multiple Dependent Claims (first time)	<input type="checkbox"/>	280	

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim
109	84	209	42	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Typed Name: Thomas D. Webster
Signature: *Thomas D. Webster*

Complete (if applicable)

Reg. Number: 39,872

Date: October 17, 2001

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on the date appearing below: *10-22-01*

By

Date

12/05/2001 CCHAU1 00000102 050840 09280567

01 FC:117 920.00 CH



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Ech

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/280,567 03/30/99 BUMOL

X-12915

0409020136

EXAMINER

HM2270629

BRANNÖCK, M

ART UNIT	PAPER NUMBER
----------	--------------

1646

21

DATE MAILED:

06/29/01

THOMAS G. PLANT, ESQ.
ELI LILLY AND COMPANY, PATENT DIVISION
LILY CORPORATE CENTER
DROP CODE 1501
INDIANAPOLIS IN 46285

Due - 7-29-01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

RECEIVED
DEC 07 2001
TECH CENTER 1600/2900

RECEIVED

JUL 06 2001

ELI LILLY AND CO.
PATENT DIVISION



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1894

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	
567			ATTORNEY DOCKET NO.

EXAMINER	
Michael Brannock	
ART UNIT	PAPER NUMBER
1648	21
DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Applicant's response to the Office Action of 6/20/00 is noted, however, Applicant's remarks will be held in abeyance because the reply filed on 4/23/01 is not fully responsive to the prior Office action 6/20/00 because of or matter(s): this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). Applicant was required to include sequence identifiers for each of the sequences in the specification that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2).

Applicant's reply is incomplete, for example, page 70 has not been amended. Applicant's cooperation is earnestly requested to identify each sequence in the application. Such sequences would be rejected by the printer once the application is allowed. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).** Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael T. Brannock, Ph.D., whose telephone number is (703) 306-5876. The examiner can normally be reached on Mondays through Fridays from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Michael T. Brannock
June 27, 2001

Yvonne Eyler